Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AIDS Treatment Activists Coalition
AIDS activists urge Tibotec to provide access to investigational drug
April 8th, 2006
AIDS activists seeking to expand access to new drugs for people living with HIV who have run out of treatment options are urging Tibotec Pharmaceuticals, a subsidiary of Johnson and Johnson, to provide compassionate access to their TMC 125 non-nucleoside HIV investigational drug. Tibotec is the first company in the battle against AIDS to have two promising new drugs simultaneously under development (TMC 114, a protease inhibitor, and TMC 125, a nonnucleoside). This is good news for patients who need access to more than one active drug to improve control of their multiple drug resistant HIV. In separate studies, both drugs have shown to help reduce viral replication in...
Source: Law & Health Weekly (2006-04-08)
|
